283 |
The Next Target of the Valvular Intervention: Future Perspectives |
Eberhard Grube |
Aug. 08. 19 |
282 |
Optimal Antithrombotics After TAVR |
Duk-Woo Park |
Aug. 08. 19 |
281 |
Who Should Not Undergo TAVR? Key Insights from the Pivotal Trials and Registries |
David Joel Cohen |
Aug. 08. 19 |
280 |
The Optimal Antithrombotic Strategy in Patients with AF and ACS: Focusing on the AUGUSTUS Trial |
Kyung Woo Park |
Aug. 08. 19 |
279 |
Clinical Challenges in CKD Patients with AF: Renal Safety of Rivaroxaban |
Hong Euy Lim |
Aug. 08. 19 |
278 |
Is LAA Closure a Valid Alternative? No, NOACs Are Strongly Preferred to LAA Closure! |
Tae-Hoon Kim |
Aug. 08. 19 |
277 |
Post LAAO Anti-thrombotic Regimens and for How Long After the Closure |
Anthony Yiu Tung Wong |
Aug. 08. 19 |
276 |
Choosing the Right Device for the Right Anatomy |
Cheung Chi Simon Lam |
Aug. 08. 19 |
275 |
Minimalist TAVR: AMC Experience |
Seung-Jung Park |
Aug. 08. 19 |
274 |
Coronary Access After TAVR |
Edgar Lik-Wui Tay |
Aug. 08. 19 |